Receptos announces plans to price public offering of its common stock

Funds used for product development, clinical trials, working capital

By Devika Patel

Knoxville, Tenn., Dec. 23 - Receptos, Inc. will price a public sale of its common stock with a greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Credit Suisse, Leerink Swann and BMO Capital Markets are the joint bookrunners. Wedbush PacGrow Life Sciences is the co-manager.

Proceeds will be used for product development, clinical trials, preclinical and research programs, working capital and other general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.